Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Empower Clinics agrees to partnership to launch US clinical trial management service

Empower Clinics Inc.

Empower Clinics CEO Steven McAuley joined Proactive's Steve Darling to share news the company has signed a Letter of Intent with Las Vegas-based nuclear medicine specialist Dr Bharat Mocherla to create and operate a Dallas-based Site Management Organization. McAuley told Proactive the end goal is to evolve this into a Contract Research Organization. The sector is booming with revenue in the neighborhood of $76 billion estimated for 2023. The partnership will give Empower the chance to work with industry, patients, community doctors and researchers in North America to provide clinical trial management services for the pharmaceutical, biotechnology and medical device industries. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com Company Website https://www.proactiveinvestors.ca/

February 08, 2023 01:27 PM Eastern Standard Time

Video

Coverage at the Speed of Life: Guarantee Trust Life Insurance Company & AmeriLife Unveil Turbo Term Life

AmeriLife

Continuing their approach to innovative product design and delivery, Guarantee Trust Life Insurance Company (“GTL”) and AmeriLife Group, LLC (“AmeriLife”) announced today the launch of Turbo Term Instant Issue Life Insurance, a revolutionary new level term life product engineered to deliver clients fully customized benefits and policy lengths to match their unique needs. “Guarantee Trust is excited to partner with AmeriLife in developing and bringing to the consumer the most dynamic term product offering in the marketplace, said Richard S. Holson III, GTL’s chairman of the board, president and CEO. “We are proud to be aligned with the great marketing organization that is AmeriLife.” With GTL’s state-of-the-art underwriting platform powered by hr | ReFlex, Hannover Re’s automated underwriting system, long application processing is a thing of the past. With a fully digital application process — and no medical exams — agents can deliver their clients an affordable policy instantly with customizable coverage, flexible benefits, a variety of level term lengths, and coverage between $100,000 and $1,000,000. For agents, Turbo Term lets them stay in the driver’s seat by owning the business they write, offering advance commissions at all levels and supporting full hierarchy, a wholly unique value proposition versus any other product on the market. “Turbo Term was built for agent distribution. No long apps. No uncomfortable medical exams. Just a fully digital application process and great, affordable, and customizable coverage to deliver the financial stability client needs – fast,” said David Paul, AmeriLife’s national sales director of Simplified Issue Life. “We’re thrilled to partner with GTL on yet another innovative product that will deliver value to the market and supercharge agent sales.” “Time and again, GTL has proven to be a valuable partner in designing products and solutions with the modern agent—and modern consumer—in mind,” added Pat Fleming, AmeriLife’s executive vice president of Product Innovation and corporate actuary. “Turbo Term will undoubtedly prove to be a great addition to AmeriLife’s portfolio of holistic solutions, and we’re excited for the opportunities it will open up for our marketers and their agents.” Turbo Term Instant Issue Life Insurance is currently available in all states except California and New York. For more information, contact your AmeriLife-affiliated marketer or independent marketing organization (IMO), or visit www.turboterm.com. Attributions and Disclaimers with Respect to Guarantee Trust Life Insurance Company Turbo Term, Individual Level Term Life Insurance, is issued on Policy Form Series ICC21-21TL, and Rider Form Series ICC21-R21ADD, ICC21-R21ADB, ICC21-R1CHILD, and ICC21-21WP by Guarantee Trust Life Insurance Company (GTL), Glenview, IL. This product’s availability, features, riders and terms under which coverage may be continued in-force or discontinued vary by state. Certain exclusions and limitations apply. For cost and complete details of coverage, please contact us or your agent. GAD18.28-22 ### About Guarantee Trust Life Insurance Company Founded in 1936, Guarantee Trust Life Insurance Company (GTL) has a proud history of providing superior insurance products and best-in-class customer service to individuals and families. Through a competitive portfolio of value-driven health, accident, life and special risk insurance products, the company offers an attractive and trusted value proposition to its policyholders and distributors while encouraging and supporting personal growth and civic involvement from its employees. For more information, visit GTLIC.com. About Hannover Re Hannover Re, with gross premium of more than EUR 33 billion, is the third-largest reinsurer in the world. It transacts all lines of property & casualty and life & health reinsurance and is present on all continents with more than 3,000 staff. Established in 1966, the Hannover Re Group today has a network of more than 170 subsidiaries, branches and representative offices worldwide. The rating agencies most relevant to the insurance industry have awarded Hannover Re outstanding insurer financial strength ratings: Standard & Poor's AA- "Very Strong" and A.M. Best A+ "Superior". For more information, please visit www.hannover-re.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Guarantee Trust Life Insurance Company Carl Leader +1 847-904-5455 cleader@gltic.com Company Website https://amerilife.com/

February 08, 2023 10:00 AM Eastern Standard Time

Sermo Healthcare Community Expands Payer & Oncologist Reach To Support Evolving Industry Needs

Sermo

Sermo, a physician-first online community and leader in global healthcare professional (HCP) insights, has expanded its platform to offer industry customers on-demand access to critical payer insights and the opportunity to build stronger connections with oncologists at a time when cancer treatment innovations are on the rise globally. The recent acquisitions of Payer Access, a leading insights provider in the U.S. payer and hospital decision-maker market followed by Charter Oak, a premier healthcare research company, support and amplify payers and oncologists on Sermo. Now, Sermo provides comprehensive reach across HCPs, payers and expert healthcare decision-makers within a single platform. Sermo’s reach into the U.S. payer market exceeds 230 million commercial lives covered. With the inclusion of Pharmacy Benefit Management companies, their reach covers virtually every commercial life in the United States. Pharmaceutical and medical device companies can leverage this highly coveted group to inform successful go-to-market strategies ranging from new product receptivity to defining win-win contracting terms. In addition to the payers expansion, Sermo is dedicated to building the Sermo Oncology Community further through its multi-channel recruitment and engagement strategy. Given the highly competitive oncology market and an ASCO-projected shortage of more than 2,200 oncologists by 2025, trusted oncologists’ insights and engagements are in high demand by the entire healthcare ecosystem. Since 2018, Sermo’s global Oncology community has grown by 28% and is projected to reach 42,000+ by the end of 2023. The growth enables Sermo to connect with more oncologists, make their voices heard on the platform and share vital insights to inform healthcare decisions around the world. “This strategic expansion is a testament to Sermo’s ongoing growth trajectory and directly fills gaps in the healthcare industry’s needs,” said Sermo CEO, Peter Kirk. “With Sermo’s global reach of 1.3 million HCPs, acquisitions such as Charter Oak and Payer Access give us increased 360-degree market visibility, added connections to the oncology community and unique access to essential audiences that directly impact outcomes for millions.” As the healthcare industry continues to evolve and tackle important trends like an increase in cancer rates among patients globally, Sermo is committed to providing a trusted platform for real-time insights and engagements among crucial stakeholder groups. These acquisitions are important milestones in Sermo’s continued M&A and growth strategy. About Sermo: Sermo turns physician experience, expertise and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries as well as the U.S. payer community, Sermo provides a unique community that fosters impactful peer-to-peer collaboration and discussions about issues that are important to healthcare constituents and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners and the medical community at large. To learn more, visit www.sermo.com. Contact Details Sermo Kite Hill PR for Sermo sermo@kitehillpr.com Company Website https://www.sermo.com/

February 08, 2023 10:00 AM Eastern Standard Time

MGC Pharmaceuticals' "numbers were very good" in Q4 2022

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive's Thomas Warner about how the business performed during the fourth quarter of 2022. Clements says that the "numbers were very good" and reveals more details about how the business is changing as it heads into a new calendar year. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2023 08:47 AM Eastern Standard Time

Video

News Release

Skye Bioscience marks SBI-100 clinical trial progress with new clinical research organization

Skye Bioscience Inc

Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials. SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness. Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. Contact Details Proactive Investors US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 08, 2023 07:19 AM Eastern Standard Time

Video

UC Asset Signed 2nd MoU to Speed Up Phase I of $4M Cannabis Deal

UC Asset LP

McapMediawire -- UC Asset LP (OTCQB: UCASU ) announced today that the company has signed second MOU on its recently announced deal of $4 million cannabis property transaction in the State of Oklahoma. Four weeks ago, UCASU entered into a MOU to acquire a 10,000 square foot cannabis cultivation property using $3 million non-cash payment, and to invest $1 million cash to build extra 5,000 square feet of facility at the same site. The new MOU details on what UCASU calls “Phase I” of the deal. In this Phase I, UC Asset will acquire 20% of ownership in the said property using non-cash payment of 500,000 preferred shares, and then will invest $1 million cash for the aforementioned expansion of the cultivation facility, while increasing UC Asset’s ownership to 50%. UC Asset will have the option to acquire the remained 50% ownership of the property by issuing 2 million preferred shares. “The updated plan of Phase I enables us to expediate the construction of the extra 5,000 square feet of cannabis cultivation facility, and therefore it will speed up the return from our investment,” claims Larry Wu, founder of UC Asset. “Now we are expecting to receive monthly payment after 3 months, in comparison to the previous plan under which we will only be paid after 6 months.” This expedition is a win-win solution for both parties, according to Wu. The State of Oklahoma will hold a special election in March to decide on marijuana legalization. It is projected that the result will be in favor of legalization. For this reason, it is very desirable to complete the said expansion of growing facility as soon as possible, possibly right after the legalization of recreational marijuana within the state. Most other terms and conditions remain the same, including the amount of monthly payment that UC Asset will receive, which will represent a 14.4% cash on cash annual return. It will still include protective terms for existing shareholders, so that the issuance of 500,000 preferred shares will not dilute the value of holdings by existing shareholders, particularly, it will not dilute dividends allocated to existing shareholders. This is possible since the preferred shares are not entitled to receive dividends unless converted into common shares, and the holder of preferred shares can only convert when revenue from the property has increased to a certain level. This 10,000 square foot cannabis property, according to UC Asset, is built to the state-of-art standard, with computerized and automatized environment control, and has the capacity to host full cycle cannabis production from creating clones/genetics to extracting cannabinoids. UC Asset has set a goal of $1 million gross profit for the year of 2023. And the speed-up of this deal will likely help UC Asset to reach that goal. About UC Asset LP UC Asset LP is a limited partnership formed for the purpose of investing in real estate with innovative strategies. For more information about UC Asset, please visit: www.ucasset.com Disclaimer: This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed. For More Information Contact: IR@UCasset.com Contact Details Larry Wu IR@UCasset.com Company Website http://www.ucasset.com/

February 07, 2023 12:43 PM Eastern Standard Time

Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

Context Therapeutics

Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial. Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer. The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added. Contact Details Proactive Investors USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 07, 2023 12:21 PM Eastern Standard Time

Video

News Release

Avicanna completes first international export of cannabis seeds between Colombia and Spain

Avicanna Inc

Avicanna CEO Aras Azadian joined Proactive's Natalie Stoberman to discuss the completion of its first export of feminized cannabis seeds to Spain. Azadian said the company's majority-owned Colombian subsidiary, Santa Marta Golden Hemp SAS, sent its first commercial export of feminized cannabis seeds to Spain. The seeds are part of the Aureus portfolio of products which also includes proprietary genetics in the form of feminized seeds, cannabinoid extracts and purified compounds including CBD, CBG and THC. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 07, 2023 12:14 PM Eastern Standard Time

Video

News Release

Braxia Scientific signs non-binding letter of intent to sell company to Irwin Naturals

Braxia Scientific Corp.

Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company has agreed to a non-binding amended and restated letter of intent for a business combination with Irwin Naturals Inc. McIntyre told Proactive the transaction assembles an experienced management and scientific team in mental health treatment, research and development. The combined company will have 17 specialized mental health clinics across North America, an enhanced telehealth platform and access to critical treatments for millions of people across multiple states in the US. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 07, 2023 12:02 PM Eastern Standard Time

Video

1 ... 164 165 166 167 168 ... 308